Sir,

We read with interest the case report of refractory hyperkalemia due to heparin abuse.\[[@ref1]\] An effect of heparin is hypoaldosteronism with hyperkalemia caused by direct inhibition of aldosterone biosynthesis and by inhibition of angiotensin-II with secondary hypoaldosteronism.\[[@ref2][@ref3]\] In present case hyperkalemia persisted irrespective of calcium gluconate, dextrose insulin, fludrocortisone, salbutamol nebulizers and slow low efficiency renal dialysis.\[[@ref1]\] Patient had acidosis, hypotension, septicemia and died of cardiac arrest.\[[@ref1]\]

The potassium-adenosine triphosphate (K-ATP) is a poor inwardly rectifying channel consisting of pore-forming and sulfonylurea - receptor subunit. The pores confer ATP inhibition while the sulfonylurea receptor is the primary target for sulfonylureas, K-ATP channel openers, and nucleoside diaphosphates.\[[@ref2]\] Hypoxia, metabolic acidosis and hypercapnia activates the K-ATP channels, resulting in vasodilatation of coronary, mesenteric, renal and smooth muscle bed and increases potassium efflux and modulates many of the kidney transport functions and maintains external potassium balance.\[[@ref3]\] The potency of sulfonylurea drugs in antagonizing vasorelaxant action of K-ATP channel stimulation after the sepsis or endotoxin is well recognized in the laboratory model.\[[@ref2]\] Reversal of the life threatening complications of hyperkalemia, vasodilator shock and severe bradycardia by the sulfonylurea inhibitor glibenclamide is a novel approach to the treatment of refractory hyperkalemia.\[[@ref4]\] In present case refractory hyperkalemia would have been rectified by glibenclamide.\[[@ref1][@ref4]\]

The authors working at critical care at tertiary care institute thus could have tried glibenclamide in their case for better outcome.\[[@ref1][@ref4]\]
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